Get the Daily Brief
Latest Biotech News
Engineered OMVs amplify CAR‑T efficacy in solid tumors
A study in Nature Biomedical Engineering reported that engineered outer membrane vesicles (OMVs) can boost CAR‑T cell activity against solid tumors. Researchers modified bacterial OMVs to deliver...
Boron neutron capture therapy preserves immunity, primes tumor response
A preclinical study published in Nature Communications demonstrated boron neutron capture therapy (BNCT) can preserve immune cell integrity while triggering robust anti-tumor immune responses in...
Lilly seals $1.2B buyout—adds oral NLRP3 drugs
Eli Lilly agreed to acquire Ventyx Biosciences for roughly $1.2 billion, taking control of a clinical-stage oral NLRP3 inhibitor program that targets inflammatory pathways implicated across...
Alumis’ TYK2 win—psoriasis stakes rewritten
Alumis reported positive Phase III results for envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints in two pivotal trials for moderate-to-severe plaque psoriasis. The...
GSK, Ionis claim Phase 3 win—bepirovirsen reaches functional cure
GSK and development partner Ionis announced positive topline results from two pivotal Phase III studies of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B that met its main...
Amgen expands oncology by buying Dark Blue—AML degrader added
Amgen struck deals to bolster its oncology pipeline by acquiring Dark Blue Therapeutics and inking related European partnerships that add targeted protein degradation programs and novel cancer...
Sanofi bets $2.56B on Earendil’s AI bispecific discovery
Sanofi signed a collaboration with Earendil Labs worth up to $2.56 billion to discover and develop bispecific antibodies for autoimmune and inflammatory diseases using Earendil’s AI-driven...
Obesity dealmaking surges—Lilly, Nimbus $1.3B; RNAi shows fat loss
Eli Lilly expanded its obesity playbook with a licensing agreement with Nimbus Therapeutics worth up to $1.3 billion to develop an oral obesity therapy, while early clinical data from Arrowhead...
HHS pares pediatric schedule—industry raises alarms
U.S. health officials revised the federal childhood immunization schedule, narrowing routine recommendations and moving several vaccines to risk‑based or shared‑decision categories. The Centers...
OpenAI rolls ChatGPT Health—seeks richer health data
OpenAI launched ChatGPT Health, a dedicated offering for health-related conversations designed to help users navigate personal health information rather than provide diagnoses. The company invited...
Rakuten raises $100M—pushes photoimmunotherapy toward FDA filing
Rakuten Medical closed a $100 million financing round to support its photoimmunotherapy platform and an ongoing Phase III trial, with company statements indicating a targeted regulatory filing...
NGS and multiomic tools advance—MD Anderson, Sophia; Illumina software
Sophia Genetics and MD Anderson announced a collaboration to co‑develop an NGS‑based oncology assay and AI-driven bioinformatics pipelines to interpret RNA‑seq and multiomic cancer data, with the...
Lilly pays $1.2B for Ventyx: adds oral NLRP3 program
Eli Lilly agreed to buy Ventyx Biosciences for $1.2 billion to add an oral NLRP3 inhibitor to its inflammation and metabolic portfolio. Ventyx’s lead candidate, VTX3232, showed biomarker and...
GSK, Ionis: bepirovirsen hits functional cure endpoints – filings planned
GSK and development partner Ionis reported positive top-line results from two pivotal Phase 3 studies of bepirovirsen, an antisense oligonucleotide aimed at functional cure for chronic hepatitis...
Amgen spends up to $1.46B – buys Dark Blue, licenses Disco target
Amgen struck multiple European deals to bolster its oncology pipeline, including an acquisition of Dark Blue Therapeutics and a license from Disco Pharmaceuticals. The transactions total up to...
Alumis’ TYK2 pill clears Phase 3 – stock surges
Alumis reported positive Phase 3 results for envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints in two pivotal psoriasis studies. The company said the trials showed high...
Arrowhead RNAi shows fat loss with tirzepatide combo – adipose proof of concept
Arrowhead Pharmaceuticals disclosed early clinical signals from RNAi programs targeting adipose biology that, when paired with Lilly’s tirzepatide (Zepbound), produced larger fat and weight...
Sanofi inks up‑to‑$2.56B Earendil deal: AI‑designed bispecifics
Sanofi signed a multi‑year collaboration with Earendil Labs valued up to $2.56 billion to discover bispecific antibodies for autoimmune diseases using Earendil’s AI platform. The pact includes...
BNCT preserves immune cells; engineered OMVs amplify CAR‑T in solid tumors
Two preclinical immuno‑oncology advances surfaced this week. A Nature Communications study showed Boron Neutron Capture Therapy (BNCT) can preserve immune cell integrity while eliciting anti‑tumor...
CNS and ocular gene‑therapy moves: non‑addictive pain therapy and intravitreal delivery pact
Academic and industry groups reported gene‑therapy advances in two distinct domains. University of Pennsylvania researchers published in Nature a cortical gene‑therapy approach that mimics opioid...